SHERIDAN, WYOMING - March 31, 2026 - Early-stage medtech companies could regain a key non-dilutive funding route in 2026 after the Senate passed legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, reducing uncertainty that has persisted since the programs' authorization lapsed on September 30, 2025. AdvaMed said the Senate action restores momentum for grants that support early research and development at startups and small manufacturers, and it urged the House of Representatives to move quickly on passage. The association framed the programs as an important bridge for companies that struggle to finance next-generation device development before products reach patients or later-stage commercial milestones.
What the Senate action changes
The legislation approved by the Senate would reauthorize SBIR and STTR, two federal programs used by small businesses and startups to fund early-stage innovation. For medtech developers, the significance is practical: program authorization had expired in late 2025, leaving a gap in certainty for companies planning grant applications, R&D staffing, and product development timelines in 2026.
AdvaMed tied the need for reauthorization to the economics of device development. Small businesses drive a large share of medtech innovation, but many face difficulty funding early research and development. The association said the programs help fill that gap through competitive grants. It also emphasized the broader policy rationale, arguing that the grants support U.S. healthcare innovation, job creation, and national leadership in medtech while helping move lifesaving and life-enhancing technologies toward patients.
Why the programs matter to medtech startups
AdvaMed said most of its more than 600 member companies are emerging and small businesses represented through its AdvaMed Accel division. That makes the funding issue directly relevant to a large share of the association's membership base rather than a narrow startup subset. In an AdvaMed survey, 89 percent of Accel members reported applying for SBIR or STTR grants, and 31 percent reported successfully securing funding.
The association also pointed to the scale of federal participation behind the programs. SBIR and STTR grants span 11 federal agencies, including the National Institutes of Health, the National Science Foundation, and the Department of Defense. For device startups, that means the programs are not limited to a single health research channel; they connect medtech innovation to biomedical research, scientific development, and defense-related technology pathways. AdvaMed argued that restoring authorization would provide certainty and confidence to startups in the early stages of product innovation.
Business impact
Procurement leads and finance executives at small medtech manufacturers now have a clearer basis for 2026 budget planning if House passage follows. Reauthorized grant programs can change capital strategy by letting teams model non-dilutive funding alongside venture financing, reducing pressure to fund every early technical milestone through equity or internal cash. That affects vendor selection, prototype spending, and decisions on when to expand external engineering, testing, or regulatory support.
R&D leaders, innovation officers, and operations directors also gain a more stable framework for roadmap decisions. With SBIR and STTR potentially back in force, companies can sequence feasibility studies, technical validation, and translational work around agency-backed grant cycles rather than delaying programs because of authorization uncertainty. For policy teams and investors, the bipartisan support cited by AdvaMed signals that early-stage medtech remains a recognized federal priority across the Senate Small Business and Entrepreneurship Committee, the House Small Business Committee, and the House Science, Space and Technology Committee. That matters in 2026 because it improves visibility into public-sector support for domestic medtech development at a point when many startups are deciding whether to advance programs, conserve cash, or seek alternative funding channels.